Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in rats

被引:8
作者
Ishiyama, S
Hiroe, M [1 ]
Nishikawa, T
Shimojo, T
Hosokawa, T
Ikeda, I
Toyozaki, T
Kasajima, T
Marumo, F
机构
[1] Tokyo Med & Dent Univ, Dept Internal Med 2, Tokyo, Japan
[2] Tokyo Womens Med Univ, Sch Med, Dept Pathol, Tokyo, Japan
[3] Otsuka Pharmaceut Co Ltd, Tokushima 77101, Japan
[4] Chiba Univ, Inst Pulm Canc Res, Div Pathol, Sch Med, Chiba, Japan
关键词
myocarditis; vesnarinone; nitric oxide; inducible nitric oxide synthase; proinflammatory cytokines;
D O I
10.1016/S0008-6363(99)00105-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Vesnarinone, a positive inotropic and immunomodulatory agent, diminishes nitric oxide (NO) levels by suppressing the induction of inducible NO synthase (iNOS) expressed in cytokine-stimulated macrophages and cardiomyocytes. We examined whether vesnarinone exerts inhibitory effects on the progression of myocardial damage in experimental autoimmune myocarditis in rats through suppression of iNOS. Methods: Myocarditis was induced in 30 Lewis rats by injection of porcine cardiac myosin and vesnarinone was orally administered to 20 of the 30 rats. On day 21 after immunization (the climax of inflammation), the hemodynamics were examined and the severity of myocarditis was evaluated by determining the area ratio (%) [affected/entire area] of myocardial lesions in histological sections. Levels of serum CK-MB, NOx (NO2- + NO3-), TNF-alpha and IL-1 beta, and cyclic GMP, iNOS mRNA, TNF-alpha and IL-1 beta in heart tissues were determined. Expression of iNOS and TNF-alpha protein were examined by immunohistochemical methods. Results: Histopathological examination revealed extensive myocardial destruction and massive infiltration of inflammatory cells in the vesnarinone-untreated rats. The area ratio of the lesions in the treated rats was significantly lower than that in the untreated ones. Levels of CK-MB, NOx, cyclic GMP, cytokines and iNOS mRNA were significantly lower in the vesnarinone-treated rats. Infiltrating macrophages and cardiomyocytes in the untreated rats showed much higher levels of expression of iNOS and TNF-alpha than those in the vesnarinone-treated rats. Conclusions: Vesnarinone may prove to be useful in the treatment of myocarditis by attenuating NO production through suppression of iNOS induced by cytokines. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:389 / 397
页数:9
相关论文
共 28 条
[11]  
Ishiyama S, 1998, J IMMUNOL, V161, P4695
[12]  
Ishiyama S, 1997, CIRCULATION, V95, P489
[13]  
Kelly RA, 1997, CIRCULATION, V95, P778
[14]   Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart [J].
Kitakaze, M ;
Minamino, T ;
Funaya, H ;
Node, K ;
Shinozaki, Y ;
Mori, H ;
Hori, M .
CIRCULATION, 1997, 95 (08) :2108-2114
[15]   INVIVO LYMPHOCYTE-MEDIATED MYOCARDIAL INJURIES DEMONSTRATED BY ADOPTIVE TRANSFER OF EXPERIMENTAL AUTOIMMUNE MYOCARDITIS [J].
KODAMA, M ;
MATSUMOTO, Y ;
FUJIWARA, M .
CIRCULATION, 1992, 85 (05) :1918-1926
[16]   Effects of vesnarinone on nitric oxide synthesis in rat cardiac myocytes [J].
Kurosaki, K ;
Ikeda, U ;
Maeda, Y ;
Shimpo, M ;
Ueno, S ;
Shimada, K .
CARDIOVASCULAR RESEARCH, 1998, 38 (01) :192-197
[17]   ELEVATED CIRCULATING LEVELS OF TUMOR-NECROSIS-FACTOR IN SEVERE CHRONIC HEART-FAILURE [J].
LEVINE, B ;
KALMAN, J ;
MAYER, L ;
FILLIT, HM ;
PACKER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (04) :236-241
[18]   TREATMENT OF VIRUS-INDUCED MYOCARDIAL INJURY WITH A NOVEL IMMUNOMODULATING AGENT, VESNARINONE - SUPPRESSION OF NATURAL-KILLER-CELL ACTIVITY AND TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION [J].
MATSUI, S ;
MATSUMORI, A ;
MATOBA, Y ;
UCHIDA, A ;
SASAYAMA, S .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (03) :1212-1217
[19]  
MATSUMORI A, 1994, BRIT HEART J, V72, P561
[20]   VESNARINONE, A NEW INOTROPIC AGENT, INHIBITS CYTOKINE PRODUCTION BY STIMULATED HUMAN BLOOD FROM PATIENTS WITH HEART-FAILURE [J].
MATSUMORI, A ;
SHIOI, T ;
YAMADA, T ;
MATSUI, S ;
SASAYAMA, S .
CIRCULATION, 1994, 89 (03) :955-958